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Using digitonin permeabilization to assay mitochondrial electron transfer, we have found that respiratory activity (succi- 
noxidase and cytochrome oxidasc) in three mouse fibroblast lines is completely eliminated by incubation with human 
recombinant umor necrosis factor-a (hrTNF). As with cytotoxicity, hrTNF-induced mitochondrial dysfunction occurs 
in resistant cells upon inhibition of protein synthesis, whereas ensitive cells exhibit spontaneous respiratory inhibition. 
In C3HA cells, inhibition is detectable 1.5-2 h after hrTNF addition, preceding cell lysis by at least 5 h (as measured 
by dye exclusion), and is approximately coincidental with morphological changes we have previously reported for this 
cell line. LM cells also exhibit inhibition of electron transfer, coincidental with morphological changes. These results 
suggest hat bioenergetic dysfunction may be involved in the cytotoxic mechanism of TNF. 
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1. INTRODUCTION 
Tumor necrosis factor-u (TNF) is a soluble pro- 
tein produced by cells of the immune system which 
was originally identified and assayed by its ability 
to cause necrosis of tumors when injected into 
animals [1,2]. It is now recognized that TNF 
belongs to a class of molecules called monokines, 
which are secreted by macrophages upon activation 
by a variety of stimuli, including exposure to cer- 
tain bacterial products [3]. In addition to induction 
of tumor necrosis in vivo, TNF possesses multiple 
immunoregulatory and inflammatory functions 
[4]; in vitro, this 17 kDa protein (active as a trimer 
[5]) is preferentially cytotoxic to many transformed 
(as well as virally infected [6]) cell lines, although 
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this specificity is not absolute [7,8]. The 
mechanism that determines ensitivity vs resistance 
to TNF may reside intracellularly, since binding to 
high-affinity receptors, internalization and de- 
gradation occur in both cell types [9,10]. In addi- 
tion, it has been shown that TNF treatment of 
resistant cells induces production of a ‘protective’ 
response, involving synthesis of a relatively small 
set of proteins [l l-131; pretreatment with protein 
synthetic inhibitors prevents this response and thus 
confers TNF sensitivity [9,8]. 
It is thus reasonable to suspect hat insight into 
the selective action of TNF toward cells can be 
gained by investigating the mechanism of cytotox- 
icity. We report that an early and dramatic intra- 
cellular event during TNF-induced cytolysis is in- 
hibition of the bioenergetic machinery of the target 
cell, specifically a virtually complete loss of mito- 
chondrial electron transfer. 
2. MATERIALS AND METHODS 
2.1. Cells and media 
Three cell lines were used, PSC3H (an SV40-transformed 
fibroblast line [14]), C3HA (a 3T3-like line [14,15]) and LM (a 
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transformed mouse fibroblast line). Cells were maintained in 
Dulbecco’s modified Eagle’s medium (DME) (Gibco) sup- 
plemented with 10% fetal calf serum (FCS) (Hyclone Labs, 
Logan, UT) and 1% glutamine, at 37°C in 5% COz. 
2.2. Assays 
All cells were counted and plated overnight prior to addition 
of hrTNF. The following morning additions of hrTNF 
(100 U/ml) and/or cycloheximide (CHX; 25 pg/ml) were made 
as designated in the figure legends, and the plates were in- 
cubated at 37°C. At the indicated times, cells were harvested by 
trypsinization, combined with the decanted media from the 
plate to include cells which were no longer adherent, washed, 
and finally resuspended to 2-10 x lo6 cells per ml in 2.7 ml 
respiration medium [0.25 M sucrose, 20 mM K+-Hepes (pH 
7.1). 10 mM MgClz] with or without (as indicated in the figure 
legends) 1 mM ADP and 2 mM potassium phosphate, and kept 
on ice. Oxygen consumption was measured with a Clark oxygen 
electrode (YSI model 5300) at 37°C with constant stirring, using 
the digitonin procedure for determining mitochondrial electron 
transfer in permeabilized cells [16,17]. Oxygen concentration 
was calibrated with air-saturated buffer, assuming 
390 ngatom/mlO2 [17]. Additions were made with a Hamilton 
syringe (volumes < 1% total) as indicated in the figures. Cell 
viability was determined by trypan blue exclusion. 
2.3. Reagents 
Digitonin was crystallized from ethanol as in [18] and added 
in dimethyl sulfoxide. hrTNF was generously supplied by Cetus 
Corp. (spec. act. 1.3 x 10’ U/mg). One unit is the amount re- 
quired to cause 50% lysis of L929 cells in the presence of 
1 pg/ml actinomycin D. All other compounds were from stand- 
ard commercial sources. 
3. RESULTS 
Fig. 1 presents a diagram depicting in the form of 
a scheme the principal components of the mito- 
chondrial electron-transfer chain, which is re- 
sponsible for cellular ATP synthesis coupled to the 
oxidation of respiratory substrate. For most of the 
data reported here, rotenone and ADP plus Pi (or 
FCCP) were added prior to initiation of measure- 
ment, the former to inhibit oxidation of endo- 
genous, NADH-linked substrate and the latter to 
induce maximal (‘state 3’) electron-transfer activi- 
ty. Upon initiation of respiration by the addition of 
succinate and digitonin (added to permeabilize the 
plasma membrane [Ia] and outer mitochondrial 
membrane [19] and thus allow accessibility of the 
added substrate to the respiratory chain), oxygen 
uptake is a measure of electron transfer through 
complexes II, III and IV (‘succinoxidase’ activity), 
and is independent of energy-coupled effects (e.g. 
respiratory control). In the absence of uncoupler 
(FCCP), a decrease in the rate of oxygen uptake 
upon subsequent addition of the ATPase inhibitor 
oligomycin is indicative of coupling between elec- 
tron transfer and ATP synthesis (‘respiratory con- 
trol’). Addition of antimycin A (which inhibits 
electron transfer through complex III) and subse- 
quent addition of the artificial electron donor 
system ascorbate/TMPD results in electron trans- 
fer exclusively through complex IV (cytochrome-c 
oxidase), since electrons from these carriers enter 
the chain at the level of cytochrome c. In this way, 
differential inhibition of two segments of the chain 
(complexes II plus III and complex IV) can be ex- 
amined, as well as an indication of the general in- 
tegrity of the mitochondrial membrane (as ex- 
hibited by respiratory control). 
PSC3H cells are an SV40-transformed mouse 
line which is normally resistant to hrTNF but 
becomes sensitive in the presence of protein syn- 
thesis inhibitors (not shown). Fig.2 shows tracings 
from a typical mitochondrial oxygen uptake assay, 
using a Clark electrode to measure dissolved ox- 
ygen in the cell suspension. Fig.2A (top tracing, 
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Fig. 1. Scheme depicting the electron flow through the mitochondrial respiratory chain. [Fe-S], iron-sulfur center. Bold arrows indicate 
site of action of inhibitors; thin arrows represent electron transfer. 
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Fig.2. Inhibition of mitochondrial electron transfer by hrTNF in 
mouse (A) PSC3H and (B) C3HA cells. Cells were prepared and 
oxygen uptake was assayed as described in section 2 in respira- 
tion medium containing ADP, Pi and rotenone (0.1 PM). Initial 
electron donor was succinate (5 mM). Additions (indicated by 
arrows): DIG, digitonin (0.015% final); AA, antimycin A 
(20 nM final); A/T, ascorbate/TMPD (1 mM and 0.2 mM 
final, respectively); OLIGO, oligomycin (0.1 PM final); FCCP, 
80 nM final. Where indicated, hrTNF (200 U/ml) or cyclohex- 
imide (25 ,ug/ml) were added to the culture and incubated for 
(A) 7 or (B) 3 h before harvest and assay. Rates of oxygen up- 
take (in ngatom/min per lo6 cells) are in parentheses. 
denoted CTRL) shows oxygen disappearance for a 
suspension of PSC3H cells treated as described 
above, with digitonin (DIG) added and with suc- 
cinate, rotenone, and ADP plus Pi present in the 
suspension buffer. The cessation in oxygen disap- 
pearance upon addition of antimycin A (AA) 
shows that this disappearance is due to mitochon- 
drial succinoxidase activity, i.e. through complexes 
II, III and IV; the respiratory rate in this experi- 
ment is 5.1 ngatom/min per lo6 cells, comparable 
in magnitude to that reported for other cultured 
mouse cells measured with this same technique 
[ 171. Subsequent addition of ascorbate/TMPD 
(A/T) results in the resumption of oxygen uptake, 
through complex IV, at a rate of 4.2 ngatom/min 
per lo6 cells. Elimination of this activity by addi- 
tion of KCN (not shown) further confirms that this 
uptake is due to mitochondrial cytochrome oxidase 
(complex IV) activity. 
The second tracing in fig.2A shows that incuba- 
tion of cells for 7 h with hrTNF (100 U/ml) plus 
cycloheximide results in virtually complete elimina- 
tion of succinoxidase activity (94% inhibition) and 
8 1% inhibition of cytochrome oxidase (since suc- 
cinoxidase activity requires complex IV function, 
this particular result indicates dysfunction in at 
least this latter segment of the electron-transfer 
chain, with no information as to additional sites of 
inhibition). The two lower traces show that (similar 
to cell lysis) inhibition of electron transfer requires 
the simultaneous presence of both hrTNF and 
cycloheximide. Studies of the time course of mito- 
chondrial inhibition in this cell line (fig.3A) show 
that little inhibition occurs prior to approx. 5 h 
after addition of hrTNF plus cycloheximide, and 
inhibition is complete after 7 h. 
In order to gain insight as to whether mitochon- 
drial inhibition is involved with an early or late 
event in the lytic process, we examined respiratory 
inhibition in C3HA cells (a 3T3-like line [15]) 
which begin to show gross morphological changes 
within l-2 h after addition of hrTNF plus cyclo- 
heximide, several hours before cell lysis is detected 
(as measured by “Cr release [20]). Fig.2B shows 
that preincubation of cells with hrTNF plus cyclo- 
heximide for 3 h results in significant mitochon- 
drial dysfunction. As with PSC3H cells, this effect 
requires the simultaneous presence of hrTNF and 
cycloheximide (not shown). The decrease in the 
rate of oxygen uptake upon addition of oligomycin 
indicates that electron transfer is coupled to ATP 
synthesis in these mitochondria, and that the effect 
of hrTNF is principally upon electron transfer and 
not energy coupling. Fig.3B shows that hrTNF (in 
the presence of cycloheximide) induces virtually 
complete inhibition of succinoxidase activity [and 
also cytochrome oxidase (not shown)] detectable 
after 1.5-2 h (coincidental with the observed mor- 
phological changes in this cell line [20]), and that 
this inhibition precedes significant cell lysis (as 
judged by trypan blue exclusion) by at least 5 h. It 
is important to point out that inhibition will only 
be detectable by this technique if a significant frac- 
tion of the total cell population is affected; this 
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Fig.3. Time course of hrTNF-induced inhibition of mitochon- 
drial electron transfer in (A) PSC3H and (B) C3HA cells. (A) 
PSC3H cells were assayed as in fig.lA. (O---O) Succinoxidase 
activity, (@-0) cytochrome oxidase activity. (B) C3HA cells 
were assayed for succinoxidase activity as described for fig.lB, 
except in respiration medium (no ADP or Pi) and in the presence 
of 80 nM FCCP. (w) Succinoxidase activity, (M) per- 
cent trypan blue-permeable cells. 
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Fig.4. Inhibition of mitochondrial electron transfer by hrTNF in 
mouse LM cells. Mouse LM cells were assayed for succinoxidase 
activity after preincubation with 100 U/ml hrTNF for the in- 
dicated times before harvest and assay as described for fig. 1. 
Rates of oxygen uptake (in ngatom/min per lo6 cells) are in 
parentheses. 
means that mitochondrial dysfunction may be oc- 
curring earlier in susceptible cells. 
LM cells are a fully transformed mouse fibro- 
blast line which are spontaneously sensitive to 
hrTNF, i.e. in the absence of inhibitors of protein 
synthesis [9]. Fig.4 (middle trace) shows that suc- 
cinoxidase activity (but not electron transfer 
through complex IV) is eliminated by treatment of 
cells with hrTNF for 8 h (after an approx. 7 h lag, 
during which time cells show no mitochondrial in- 
hibition [not shown] and which is generally coin- 
cidental with morphological degeneration [20], and 
exhibit no microscopically detectable ffects [20]), 
and the bottom tracing shows that inhibition of 
complex IV ensues rapidly afterward (by 9 h). 
4. DISCUSSION 
Research to date on the mechanism of cytotoxicy 
induced by TNF has largely employed cell lysis 
assays (e.g. release of internal isotope or dye reten- 
tion), which can be viewed as the end product of 
the entire cell death process [21] (i.e. lysis of the 
plasma membrane). In an effort to gain specific in- 
sight into the sequence of events which ultimately 
results in TNF-induced cell death, recent work 
from this laboratory has focussed on examination 
of cellular events preceding lysis, in particular mor- 
phological [20] and cytoskeletal [22] changes. 
Here, we report a metabolic abnormality in target 
cells which also precedes lysis, specifically, dys- 
function in the mechanism of cellular energy pro- 
duction. We note that mitochondrial inhibition oc- 
curs in both of two cell types (C3HA and LM) 
which exhibit different morphological changes dur- 
ing TNF-induced cell death [20]; in addition, the 
onset of such inhibition is approximately coin- 
cidental with these changes. 
In vitro, exposure of activated macrophages to 
neoplastic cells induces a nonphagocytic response, 
resulting in target cell cytostatis and cytotoxicity 
[3,23]. Studies have shown that under these condi- 
tions tumor cells develop inhibition of mitochon- 
drial respiration [17,24], similar in pattern to that 
reported here for LM cells (i.e. preferential 
[although not completely selective] inhibition of 
complexes II and III as opposed to complex IV 
[17]). Although cell-cell contact between the 
macrophage and the tumor target cell has been 
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reported to be required [25], a soluble factor has 
been identified which induces mitochondrial dys- 
function in murine mammary adrenocarcinoma 
cells [26]. It has recently been shown that TNF is a 
major mediator of monocyte cytotoxicity towards 
neoplastic cells [27-291, and that TNF is produced 
by macrophages as both a soluble, secreted and a 
membrane-bound form [30-331; TNF-target cell 
interaction occurs by both cell-cell contact and by 
release of soluble cytotoxin. The present data thus 
suggest that macrophage-induced target cell 
respiratory dysfunction may be mediated by TNF, 
whether by cell-cell contact or through release of 
the soluble protein. 
The most important question concerning the 
results presented here with regard to the cellular 
mechanism of TNF cytotoxicity is whether the 
mitochondrial inhibition of electron transfer is a 
cause or an effect. The occurrence of this inhibition 
in each of three cell lines investigated (and only 
under conditions which lead to eventual cell lysis) 
and the time course of inhibition in relation to cell 
lysis (at least in C3HA cells, where mitochondrial 
dysfunction precedes significant cell lysis by at 
least 5 h) suggest hat this inhibition is an impor- 
tant part of the mechanism of cytotoxicity. The 
simultaneous occurrence of mitochondrial dys- 
function and morphological changes in two lines 
(as described above) also supports this conclusion. 
Other intracellular events have been described 
upon treatment of sensitive cells with TNF, in- 
cluding activation of phospholipase A2 [34-361, in- 
creased intracellular CAMP levels [37], and increas- 
ed ADP-ribosylation activity [38]. Although fur- 
ther experimentation is required to delineate the 
relationships between these effects and the 
mechanism of cytotoxicity (specifically, the dif- 
ferentiation between signalling events and induc- 
tion of cell vital damage), cellular mitochondrial 
dysfunction might be expected to produce abnor- 
malities in a variety of cellular processes, including 
energy metabolism (and consequent effects on 
anabolic and regulatory functions [39]), cyto- 
skeletal integrity [40-421, and intracellular solute 
and ion (including calcium [42,43]) homeostasis. In 
addition, the mitochondrial electron-transfer chain 
(primarily complex III [44]) is a major intracellular 
source of reactive oxygen intermediates [45,46], 
which have also been implicated in TNF-mediated 
cell cytotoxicity [47-491. 
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